Renal cell carcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:06:24 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Renal cell carcinoma stage IV – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study Comparing Nivolumab and Ipilimumab with Sunitinib for Patients with Advanced or Metastatic Kidney Cancer https://clinicaltrials.eu/trial/study-comparing-nivolumab-and-ipilimumab-with-sunitinib-for-patients-with-advanced-or-metastatic-kidney-cancer/ Wed, 29 Apr 2026 14:23:22 +0000 https://clinicaltrials.eu/trial/study-comparing-nivolumab-and-ipilimumab-with-sunitinib-for-patients-with-advanced-or-metastatic-kidney-cancer/ This clinical trial is focused on studying a type of kidney cancer known as advanced or metastatic renal cell carcinoma. The study is comparing two different treatment approaches for this condition. One group of participants will receive a combination of two medications, Nivolumab and Ipilimumab, while the other group will receive a single medication called Sunitinib. Nivolumab and Ipilimumab are given as an infusion, which means they are administered directly into the bloodstream through a vein. Sunitinib is taken orally in the form of capsules.

The purpose of the study is to compare how well these treatments work in terms of how long patients live and how long they live without the cancer getting worse. Participants in the study will be randomly assigned to one of the two treatment groups. The study will follow participants over a period of time to monitor their health and the effects of the treatments. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments.

Throughout the study, participants will have regular check-ups and tests to assess their health and the progress of their cancer. The study aims to provide valuable information on the effectiveness and safety of these treatments for people with advanced or metastatic renal cell carcinoma. This research could help improve future treatment options for this type of cancer.

]]>